New Diabetes Drug Shows Promise against Alzheimer’s Disease
A ‘triple receptor’ drug originally created to treat type 2 diabetes could be used to treat Alzheimer’s disease after researchers from China and the United Kingdom found it ‘significantly reversed memory loss’ in mice. The research appears in the journal Brain Research.
“The novel treatment holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease,” said co-author Professor Christian Holscher, from Lancaster University.
This is the first time that a triple receptor drug has been used which acts in multiple ways to protect the brain from degeneration.
It combines glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon, which are all growth factors.
Read more: http://bit.ly/2qgp1h0
“The novel treatment holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease,” said co-author Professor Christian Holscher, from Lancaster University.
This is the first time that a triple receptor drug has been used which acts in multiple ways to protect the brain from degeneration.
It combines glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon, which are all growth factors.
Read more: http://bit.ly/2qgp1h0
